Adaptive Biotechnologies (NASDAQ:ADPT) CFO Kyle Piskel Sells 3,115 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CFO Kyle Piskel sold 3,115 shares of Adaptive Biotechnologies stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $13.04, for a total value of $40,619.60. Following the sale, the chief financial officer directly owned 256,725 shares of the company’s stock, valued at approximately $3,347,694. The trade was a 1.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kyle Piskel also recently made the following trade(s):

• On Wednesday, March 11th, Kyle Piskel sold 18,672 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.17, for a total value of $245,910.24.

Adaptive Biotechnologies Price Performance

ADPT stock opened at $13.96 on Thursday. Adaptive Biotechnologies Corporation has a fifty-two week low of $8.50 and a fifty-two week high of $20.76. The stock has a market capitalization of $2.23 billion, a price-to-earnings ratio of -42.30 and a beta of 2.16. The business’s fifty day moving average price is $13.81 and its two-hundred day moving average price is $15.65.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The business had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. During the same period in the prior year, the company posted ($0.20) earnings per share. Adaptive Biotechnologies’s revenue was up 35.1% compared to the same quarter last year. Research analysts expect that Adaptive Biotechnologies Corporation will post -0.48 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Piper Sandler set a $21.00 target price on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Guggenheim reiterated a “buy” rating and issued a $21.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Morgan Stanley lowered their price objective on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.57.

Institutional Trading of Adaptive Biotechnologies

A number of institutional investors and hedge funds have recently made changes to their positions in ADPT. AQR Capital Management LLC increased its stake in Adaptive Biotechnologies by 45.8% in the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock valued at $2,265,000 after acquiring an additional 97,444 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Adaptive Biotechnologies by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock worth $511,000 after purchasing an additional 2,914 shares during the last quarter. Caxton Associates LLP acquired a new stake in shares of Adaptive Biotechnologies in the 1st quarter valued at $93,000. New York State Common Retirement Fund boosted its holdings in shares of Adaptive Biotechnologies by 39.2% in the 2nd quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock valued at $551,000 after purchasing an additional 13,300 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in shares of Adaptive Biotechnologies by 728.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock valued at $4,417,000 after purchasing an additional 333,379 shares in the last quarter. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.